


# H1 2025 Highlights

"Our half year results reflect continued strong momentum, with growth across all three therapeutic areas, particularly in our Rare Disease franchise, which is expanding rapidly and progressing well"




**David Loew**  
Chief Executive Officer



## Geographic Breakdown

Total sales by region: 2025





**North America**  
**35%**  
of total sales

**Europe**  
**40%**  
of total sales

**RoW**  
**25%**  
of total sales

In this map, Europe is defined as the E.U., the U.K., Iceland, Liechtenstein, Norway, and Switzerland.



## Pipeline Progression

**Cabometyx®**: EU approval in NETs<sup>2</sup>

**IPN10200**: Initiation of Phase II in Cervical Dystonia

**Tovorafenib**: Regulatory filing with EMA

## H2 2025 Progression

**Fidrisertib**: Pivotal data readout in FOP<sup>3</sup>

**LANT<sup>4</sup>**: Proof-of-concept data readout in aesthetics